Cargando…

A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis

PURPOSE: Cisplatin resistance is the major obstacle in the clinical treatment of ovarian cancer patients. Molecular mechanisms of cisplatin resistance are multifaceted. Gold(I)-compounds, i.e. N-heterocyclic carbene-gold(I)-complexes (NHC-Au(I)) has been regarded as promising cytotoxic drug candidat...

Descripción completa

Detalles Bibliográficos
Autores principales: König, Philipp, Zhulenko, Roman, Suparman, Eloy, Hoffmeister, Henrik, Bückreiß, Nico, Ott, Ingo, Bendas, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261188/
https://www.ncbi.nlm.nih.gov/pubmed/37272932
http://dx.doi.org/10.1007/s00280-023-04548-1
_version_ 1785057898697588736
author König, Philipp
Zhulenko, Roman
Suparman, Eloy
Hoffmeister, Henrik
Bückreiß, Nico
Ott, Ingo
Bendas, Gerd
author_facet König, Philipp
Zhulenko, Roman
Suparman, Eloy
Hoffmeister, Henrik
Bückreiß, Nico
Ott, Ingo
Bendas, Gerd
author_sort König, Philipp
collection PubMed
description PURPOSE: Cisplatin resistance is the major obstacle in the clinical treatment of ovarian cancer patients. Molecular mechanisms of cisplatin resistance are multifaceted. Gold(I)-compounds, i.e. N-heterocyclic carbene-gold(I)-complexes (NHC-Au(I)) has been regarded as promising cytotoxic drug candidates. However, their potential to overcome cisplatin resistance has hardly been addressed yet. Here we investigated the activity of the gold(I) drug auranofin and the NHC-Au(I)-compound MC3 in W1CR and A2780cis cisplatin-resistant ovarian cancer cells. METHODS: Cytotoxicity of auranofin and MC3 was detected by MTT assay, correlated with intracellular gold(I) content, analyzed by AAS, and with flow cytometric detection of the cell cycle. Insight into cellular redox balance was provided by fluorimetric ROS-formation assay and western blotting thioredoxin (Trx) and Nrf2. The role of ERK was elucidated by using the inhibitor SCH772984 and its impact on cytotoxicity upon co-treatment with cisplatin and Au(I)-compounds, respectively. RESULTS: MC3 overcomes cisplatin resistance in A2780cis and W1CR, and auranofin in W1CR cells completely, which is neither reflected by intracellular gold levels nor cell cycle changes. Upregulated redox balance appears as a basis for resistance. W1CR cells possess higher Trx levels, whereas A2780cis cells display strong Nrf2 expression as anti-oxidative protection. Nevertheless, overcoming redox balance appears not primary mode of activity comparing cisplatin and gold(I)-compounds. pERK emerges as a critical component and thus a promising target for overcoming resistance, regulating apoptosis differently in response to either gold(I) or cisplatin in A2780 cells. CONCLUSION: These data reflect the complexity of cisplatin resistance in cell models and emphasize NHC-Au(I)-complexes as prospective cytotoxic agents for further investigations in that respect. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00280-023-04548-1.
format Online
Article
Text
id pubmed-10261188
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-102611882023-06-15 A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis König, Philipp Zhulenko, Roman Suparman, Eloy Hoffmeister, Henrik Bückreiß, Nico Ott, Ingo Bendas, Gerd Cancer Chemother Pharmacol Original Article PURPOSE: Cisplatin resistance is the major obstacle in the clinical treatment of ovarian cancer patients. Molecular mechanisms of cisplatin resistance are multifaceted. Gold(I)-compounds, i.e. N-heterocyclic carbene-gold(I)-complexes (NHC-Au(I)) has been regarded as promising cytotoxic drug candidates. However, their potential to overcome cisplatin resistance has hardly been addressed yet. Here we investigated the activity of the gold(I) drug auranofin and the NHC-Au(I)-compound MC3 in W1CR and A2780cis cisplatin-resistant ovarian cancer cells. METHODS: Cytotoxicity of auranofin and MC3 was detected by MTT assay, correlated with intracellular gold(I) content, analyzed by AAS, and with flow cytometric detection of the cell cycle. Insight into cellular redox balance was provided by fluorimetric ROS-formation assay and western blotting thioredoxin (Trx) and Nrf2. The role of ERK was elucidated by using the inhibitor SCH772984 and its impact on cytotoxicity upon co-treatment with cisplatin and Au(I)-compounds, respectively. RESULTS: MC3 overcomes cisplatin resistance in A2780cis and W1CR, and auranofin in W1CR cells completely, which is neither reflected by intracellular gold levels nor cell cycle changes. Upregulated redox balance appears as a basis for resistance. W1CR cells possess higher Trx levels, whereas A2780cis cells display strong Nrf2 expression as anti-oxidative protection. Nevertheless, overcoming redox balance appears not primary mode of activity comparing cisplatin and gold(I)-compounds. pERK emerges as a critical component and thus a promising target for overcoming resistance, regulating apoptosis differently in response to either gold(I) or cisplatin in A2780 cells. CONCLUSION: These data reflect the complexity of cisplatin resistance in cell models and emphasize NHC-Au(I)-complexes as prospective cytotoxic agents for further investigations in that respect. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00280-023-04548-1. Springer Berlin Heidelberg 2023-06-05 2023 /pmc/articles/PMC10261188/ /pubmed/37272932 http://dx.doi.org/10.1007/s00280-023-04548-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
König, Philipp
Zhulenko, Roman
Suparman, Eloy
Hoffmeister, Henrik
Bückreiß, Nico
Ott, Ingo
Bendas, Gerd
A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
title A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
title_full A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
title_fullStr A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
title_full_unstemmed A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
title_short A biscarbene gold(I)-NHC-complex overcomes cisplatin-resistance in A2780 and W1 ovarian cancer cells highlighting pERK as regulator of apoptosis
title_sort biscarbene gold(i)-nhc-complex overcomes cisplatin-resistance in a2780 and w1 ovarian cancer cells highlighting perk as regulator of apoptosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261188/
https://www.ncbi.nlm.nih.gov/pubmed/37272932
http://dx.doi.org/10.1007/s00280-023-04548-1
work_keys_str_mv AT konigphilipp abiscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT zhulenkoroman abiscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT suparmaneloy abiscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT hoffmeisterhenrik abiscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT buckreißnico abiscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT ottingo abiscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT bendasgerd abiscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT konigphilipp biscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT zhulenkoroman biscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT suparmaneloy biscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT hoffmeisterhenrik biscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT buckreißnico biscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT ottingo biscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis
AT bendasgerd biscarbenegoldinhccomplexovercomescisplatinresistanceina2780andw1ovariancancercellshighlightingperkasregulatorofapoptosis